Abstract: The invention relates methods for diagnosing patients with multiple sclerosis by detecting cell free nucleosomes as biomarkers in body fluid samples.

Abstract: The invention relates to using cell free nucleosome levels to identify patients at risk of developing a NETosis associated adverse reaction to the infection. The methods are used to monitor the progress of a disease and assigning a risk of an adverse outcome in a patient suffering from an infection.

Abstract: The invention relates to using cell free nucleosome levels to identify patients at risk of developing a NETosis associated adverse reaction to the infection. The methods are used to monitor the progress of a disease and assigning a risk of an adverse outcome in a patient suffering from an infection.

Abstract: The invention relates to cell free nucleosomes as biomarkers in plasma samples for vascular or haematological cancers.

Abstract: The invention relates to the use of histone binding agents for detecting, isolating and/or purifying cell free nucleosomes of tumor origin or circulating tumor DNA from a biological sample. The invention also relates to methods and kits using said histone binding agents.

Abstract: The invention relates to a body fluid test method for the detection and treatment of prostate cancer, in particular aggressive prostate cancer. It also relates to monitoring of patients with low risk prostate tumours and selection of patients for prostate biopsy as well as selection of patients for prostate surgery or therapy.

Abstract: The invention relates to methods for separating circulating cell free nucleosomes comprising linker DNA from a biological fluid sample, in particular nucleosomes of disease origin. Such methods allow for improved analysis of genetic and epigenetic markers associated with nucleosomes of disease origin.

Abstract: The invention relates to body fluid test methods for the detection of cancer using a combination biomarker panel comprising at least one cytokine molecule and at least one cell free chromatin fragment.

Abstract: The invention relates to a method for detecting and measuring the presence of nucleosome-protein adducts and the use of such measurements for the detection and diagnosis of disease. The invention also relates to a method of identifying nucleosome adduct biomarkers for the detection and diagnosis of disease and to biomarkers identified by said method.

Abstract: The present invention relates to the use of a histone H1 binding agent for detecting, isolating and/or purifying cell free nucleosomes of tumor origin from a biological sample. The invention also describes methods of negative or positive selection using histone H1 binding agents, in order to enrich a sample for cell free nucleosomes of tumor origin.

Abstract: The present invention relates to a method for detecting and measuring the presence of cell free mono-nucleosomes and oligo-nucleosomes that contain histone H1 or a histone H1 modification, variant or isoform, and the use of such measurements for the detection and diagnosis of disease.

Abstract: The present invention relates to the use of a histone H1 binding agent for detecting, isolating and/or purifying cell free nucleosomes of tumor origin from a biological sample. The invention also describes methods of negative or positive selection using histone H1 binding agents, in order to enrich a sample for cell free nucleosomes of tumor origin.

Abstract: The present invention relates to the use of a histone H1 binding agent for detecting, isolating and/or purifying cell free nucleosomes of tumor origin from a biological sample. The invention also describes methods of negative or positive selection using histone H1 binding agents, in order to enrich a sample for cell free nucleosomes of tumor origin.

Abstract: The present invention relates to a method for detecting and measuring the presence of cell free mono-nucleosomes and oligo-nucleosomes that contain histone H1 or a histone H1 modification, variant or isoform, and the use of such measurements for the detection and diagnosis of disease.

Abstract: The present invention provides a method for analysing nuclease hypersensitive sites which method comprises: i) cleaving a nucleic acid sample comprising chromatin at multiple nuclease hypersensitive sites with a first sequence specific restriction enzyme to introduces a staggered cut and leave a single chain 3? or 5? overhang in a double stranded DNA; ii) optionally isolating substantially free DNA from the digested nucleic acid sample or removing the protein and RNA components from the digested nucleic acid sample to leave substantially free DNA; iii) ligating an adapter oligonucleotide onto the overhang produced by the first sequence specific restriction enzyme in aqueous solution, which adaptor oligonucleotide contains a single stranded region which is complementary to the overhang produced by the first sequence specific restriction enzyme, and which adaptor oligonucleotide contains a recognition site (e.g.

Abstract: The invention relates to the use of histone binding agents for detecting, isolating and/or purifying cell free nucleosomes of tumor originor circulating tumor DNA from a biological sample. The invention also relates to methods and kits using said histone binding agents.

Abstract: The invention relates to a method for detecting the presence of a gynaecological growth, in particular for the diagnosis of endometriosis. The invention also relates to a method of identifying a biomarker for detecting the presence of a gynaecological growth and to biomarkers identified by said method.

Abstract: The invention relates to a method for detecting and measuring the presence of nucleosome-protein adducts and the use of such measurements for the detection and diagnosis of disease. The invention also relates to a method of identifying nucleosome adduct biomarkers for the detection and diagnosis of disease and to biomarkers identified by said method.

Abstract: The invention relates to a method for detecting and measuring the presence of nucleosome-protein adducts and the use of such measurements for the detection and diagnosis of disease. The invention also relates to a method of identifying nucleosome adduct biomarkers for the detection and diagnosis of disease and to biomarkers identified by said method.

Abstract: The invention relates to a method for detecting and measuring the presence of mono-nucleosomes and oligo-nucleosomes and nucleosomes that contain particular histone modifications and the use of such measurements for the detection and diagnosis of disease. The invention also relates to a method of identifying histone modification biomarkers for the detection and diagnosis of disease and to said histone modification biomarkers identified by said method.